-
Wegovy weight loss pill is now available for sale in U.S.The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly.HealthJan 6
-
The Wegovy weight loss pill could come to Canada. What we knowThe FDA approved the one-a-day Wegovy pill, the first oral GLP-1 medication for obesity in the U.S., Wegovy manufacturer Novo Nordisk said in a statement Tuesday.HealthDec 24, 2025
-
U.S. FDA approves Wegovy weight-loss pill in industry firstThe approval gives Novo Nordisk a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.HealthDec 22, 2025
-
Generic Ozempic can be made in Canada as of next week. Will it be cheaper?As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy.HealthJan 2
-
Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talksNegotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.HealthDec 3, 2025
-
Trump says prices for Ozempic, other weight-loss drugs to drop in U.S.Trump, Eli Lilly and Novo Nordisk unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for government health insurance programs, as well as for cash payers.U.S. NewsNov 6, 2025
-
Health Canada approves 1st GLP-1 daily pill. Here’s who can take itThe once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.CanadaJan 12
-
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo NordiskNEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy.HealthNov 8, 2025
-
Trump unveils deal to expand coverage and lower costs on obesity drugsWASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.HealthNov 6, 2025
-
Many regain weight after stopping GLP-1 drugs, data shows. Here’s whyPeople on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.HealthJan 8
-
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark’s Novo NordiskPfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.HealthOct 31, 2025
-
Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding warThe market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.HealthOct 30, 2025
-
Ozempic, Wegovy makers Novo Nordisk announce 9K layoffs in restructuringOzempic and Wegovy maker Novo Nordisk says it will layoff about 9,000 employees of its global workforce as it restructures in an attempt to fend off competition.WorldSep 10, 2025
-
Unheard. Unserved. A woman’s battle for a PCOS diagnosis, and how no one was listeningBrooke Sears fought to get her diagnosis after doctors said she needed to lose weight. Her story is part of a Global News series on health care and how it's failing many women.FeaturesSep 24, 2025
-
Ozempic approved in Canada to reduce kidney decline in people with diabetesThe patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes.HealthAug 19, 2025
-
University of Manitoba studies Ozempic marketingResearchers at the University of Manitoba are looking at how marketing for drugs like Ozempic and Wegovy influence peoples' views on food, hunger, and weight.HealthJul 23, 2025
-
Ozempic, Wegovy linked to rare cases of eye disorder, EMA saysCalled non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.ConsumerJun 6, 2025
-
Weight-loss drug Wegovy use is up 50% among U.S. teens, study showsA new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.HealthJun 3, 2025
-
Drugs like Ozempic may lower cancer risk if you have diabetes: studyExcess body weight can raise the risk of certain cancers, leading researchers to wonder whether drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.HealthMay 23, 2025
-
Zepbound beats Wegovy rival in 1st head-to-head weight loss studyPeople taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.HealthMay 12, 2025